Indoco Remedies Q1FY27 Unaudited Results: Standalone Profit ₹823 Crore, Consolidated ₹654 Crore
Indoco Remedies reported Q1FY27 unaudited standalone net profit of ₹82.32 crore, a significant increase from ₹27.36 crore in Q4FY26 and a loss in Q1FY26. Consolidated net profit was ₹65.44 crore, up from ₹23.68 crore in Q4FY26 and a loss in Q1FY26. Total income from operations was ₹408.97 crore (standalone) and ₹467.50 crore (consolidated).
The substantial increase in profits and positive turnaround from losses is a material event that is likely to have a significant impact on investor perception and the company's stock performance.
The company reported a significant improvement in net profit for both standalone and consolidated results compared to the previous quarter and the same quarter last year, indicating positive financial performance.
Indoco Remedies Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a standalone net profit after tax of ₹8,232 lakhs (₹82.32 crore) for the quarter ended June 30, 2026. This compares to a standalone net profit of ₹2,736 lakhs (₹27.36 crore) in the previous quarter ended March 31, 2026, and a standalone net loss of ₹2,807 lakhs (₹28.07 crore) in the same quarter last year ended June 30, 2025.
On a consolidated basis, the company posted a net profit after tax of ₹6,544 lakhs (₹65.44 crore) for the quarter ended June 30, 2026. This is an improvement from a consolidated net profit of ₹2,368 lakhs (₹23.68 crore) in the preceding quarter ended March 31, 2026, and a consolidated net loss of ₹3,635 lakhs (₹36.35 crore) in the corresponding quarter last year ended June 30, 2025.
The total income from operations for the quarter ended June 30, 2026, stood at ₹40,897 lakhs (₹408.97 crore) on a standalone basis, and ₹46,750 lakhs (₹467.50 crore) on a consolidated basis.
These results were reviewed by the Audit Committee and approved by the Board of Directors on July 28, 2026. The detailed financial results have been published in Business Standard (English) and Mumbai Lakshadeep (Marathi) on July 29, 2026.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.